Innovation Gaps on Life Science Frontiers? - from Ebola, Zika and bad bugs to new uses, big data and the black box Prof. Dr. Timo Minssen, University of Copenhagen OIPRC Invited Speaker Series University of Oxford (UK) This presentation is based on an ongoing paper collaboration with Dr.Nicholson Price, University of Michigan and Dr. Kathy Liddell, University of Cambridge
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Innovation Gaps on Life Science Frontiers?
- from Ebola, Zika and bad bugs to new uses, big data and the black box
Prof. Dr. Timo Minssen, University of Copenhagen
OIPRC Invited Speaker Series
University of Oxford (UK)
This presentation is based on an ongoing paper collaboration with
Dr.Nicholson Price, University of Michigan and
Dr. Kathy Liddell, University of Cambridge
Starting point: Patents
A Paradigm Shift in the Pharma & Health Care Sectors ??????
A. Patent mechanics
1. Prosecution/Acquisition 2. Litigation/Enforcement
B. Problems translating social welfare
1. Differential ability to pay 2. Payment distortions 3. Scientific phenomenon (ex: AB/AM resistance)
Multiple reasons for patent “limits”/gaps
1. Biologics & biosimilars
2. Diagnostics and “black box” precision medicine
3. New uses for known drugs
4. Orphan drugs (rare & neglected deseases)
5. Manufacturing of small molecule drugs
6. Manufacturing of Biologics & Biosimilars
7. Antibiotics
A. Patent changes
B. Regulatory exclusivities
C. Money - Prizes
- Grants
- Tax Incentives
- Reimbursement
D. Individually tailored solutions - Priority Review Vouchers
- GAIN & corresponding European initiatives
- Integrated solutions
Interventions
Insuffient policy coordination ?(FDA/EMA, CMS, CAFC, PTO/EPO, EU/US Congress)
Little academic coordination
Coordination from industry?
Insufficient dialogue between decision makers academia, patients and industry?
Misinformed debates
Coordination, collaboration and exchange of information?
Effects of proposed solutions?
CatalogingLinking InformingReaching out for input!Call for action?Synthesis?
Why are we writing this paper?
CIIR’s Copenhagen Biotech and Pharma Forum (CBPF)
Copenhagen Summer School in Pharma Law and Policy
Courses in EU Life Science & Health Law
Major cross-faculty projects in Biobanks, Sys/SynBio, etc.
Copenhagen Center for Regulatory Sciences (CORS)
Collaboration with open innovation projects at Leo Pharma, Novozymes etc.
Application for Center of Excellence for Biomedical Innovation Law (CeBIL)
UCPH activities regarding legal challenges to biomedical innovation
What do you think?
Related Documents
